Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | ADCY5 | O95622 | 5/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.33 |
| ▸ | FHIT | P49789 | 2/20 | 0.33 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20691939 | 0.89 | P2RY1 (0.40) | P2RY1ADCY5DGAT1FDPSENPP1 | |
| SCHEMBL20691298 | 0.83 | AHCY (0.37) | P2RY1TYMPFDPSENPP1 | |
| SCHEMBL24258586 | 0.81 | TAS1R3 (0.42) | P2RY1 | |
| SCHEMBL20691935 | 0.81 | P2RX3 (0.42) | TYMP | |
| SCHEMBL20691971 | 0.81 | ADCY5 (0.35) | P2RY1ADCY5TYMPDGAT1 | |
| SCHEMBL20691301 | 0.77 | TYMP (0.47) | TYMP | |
| SCHEMBL20691336 | 0.72 | RNASEL (0.42) | P2RY1FDPS | |
| SCHEMBL9471687 | 0.72 | ADCY5 (0.44) | P2RY1ADCY5TYMP | |
| SCHEMBL24681005 | 0.71 | ADCY5 (0.55) | P2RY1ADCY5ENPP1P2RY11 | |
| SCHEMBL20806101 | 0.70 | TAS1R3 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3658565-B1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2019023459-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-31 | — | — | WO | disclosed |